Differences of satisfaction with medication between patients with schizophrenia treated with typical antipsychotics and atypical antipsychotics

被引:8
作者
Watanabe, A
Shibata, I
Kato, T
机构
[1] Kujira Hosp, Yawatahama, Ehime 7968010, Japan
[2] Kawaguchi Hosp, Saitama, Japan
[3] RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Saitama, Japan
关键词
attitude to health; atypical antipsychotic agents; personal satisfaction; quality of life; side-effect;
D O I
10.1111/j.1440-1819.2004.01230.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Many studies have demonstrated that atypical antipsychotics are superior to typical antipsychotics in that they have fewer side-effects and produce better improvement of cognitive deficits and quality of life in patients with schizophrenia. However, most of these studies dealt with objective indices assessed by researchers rather than subjective indices that are indeed important to patients themselves. In 126 patients with schizophrenia, annoyance of side-effects and psychotic symptoms, satisfaction with medication, wish to change medication, and knowledge of atypical antipsychotics were assessed using questionnaires. Patients treated with typical antipsychotics complained less of annoyance of poor attention and concentration than those treated with atypical antipsychotics, which can be explained by increased awareness of these symptoms by the patients due to the improvement of cognitive function. There were no significant differences between the two groups in other variables. The present results that satisfaction and annoyance were similar between patients treated with typical antipsychotics and those with atypical antipsychotics, may partly explain why patients hesitated and rejected changing or shifting from typical to atypical antipsychotics. But because 98 of 126 patients did not know about atypical antipsychotics, it is important to educate the patients on the merits of atypical antipsychotics.
引用
收藏
页码:268 / 273
页数:6
相关论文
共 29 条
[1]  
Aoba A, 2001, Seishin Shinkeigaku Zasshi, V103, P523
[2]   Patients subjective experiences on antipsychotic medications: Implications for outcome and quality of life [J].
Awad, AG ;
Hogan, TP ;
Voruganti, LNP ;
Heslegrave, RJ .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :123-132
[3]   Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial [J].
Beasley, CM ;
Hamilton, SH ;
Crawford, AM ;
Dellva, MA ;
Tollefson, GD ;
Tran, PV ;
Blin, O ;
Beuzen, JN .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (02) :125-137
[4]  
BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94
[5]   QUALITY OF LIFE IN CANCER-PATIENTS - AN HYPOTHESIS [J].
CALMAN, KC .
JOURNAL OF MEDICAL ETHICS, 1984, 10 (03) :124-127
[6]   Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study [J].
Cuesta, MJ ;
Peralta, V ;
Zarzuela, A .
SCHIZOPHRENIA RESEARCH, 2001, 48 (01) :17-28
[7]   Subject and observer-rated quality of life in schizophrenia [J].
Fitzgerald, PB ;
Williams, CL ;
Corteling, N ;
Filia, SL ;
Brewer, K ;
Adams, A ;
de Castella, RA ;
Rolfe, T ;
Davey, P ;
Kulkarni, J .
ACTA PSYCHIATRICA SCANDINAVICA, 2001, 103 (05) :387-392
[8]   The importance of social comparisons for high levels of subjective quality of life in chronic schizophrenic patients [J].
Franz, M ;
Meyer, T ;
Reber, T ;
Gallhofer, B .
QUALITY OF LIFE RESEARCH, 2000, 9 (05) :481-489
[9]  
GEBHARDT R, 1972, PHARMAKOPSYCH NEURO, V5, P295
[10]   Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis [J].
Geddes, J ;
Freemantle, N ;
Harrison, P ;
Bebbington, P .
BRITISH MEDICAL JOURNAL, 2000, 321 (7273) :1371-1376